9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Propagandas de medicamentos psicoativos: análise das informações científicas Translated title: Psychoactive drug advertising: analysis of scientific information

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          OBJETIVO: Segundo a Organização Mundial da Saúde, as propagandas de medicamentos devem ser fidedignas, exatas, verdadeiras, informativas, equilibradas, atualizadas e passíveis de comprovação. O objetivo do estudo foi avaliar as propagandas de medicamentos psicoativos divulgadas a médicos, em relação à concordância das informações contidas nas peças publicitárias com as suas respectivas referências bibliográficas e à acessibilidade dessas referências citadas. MÉTODOS: A coleta de dados foi realizada durante o ano de 2005, em Araraquara, SP. Foram coletadas e analisadas propagandas de 152 medicamentos, num total de 304 referências. As referências bibliográficas foram solicitadas aos serviços de atendimento ao cliente dos laboratórios e consultadas nas bibliotecas da rede UNESP (Ibict, Athenas), BIREME (SciELO, PubMed, periódicos catalogados de acesso livre) e periódicos CAPES. As afirmações das propagandas foram conferidas com as das referências por meio da técnica de análise de conteúdo. RESULTADOS: Das referências citadas nas propagandas, 66,7% foram acessadas. De 639 afirmações identificadas, foi possível analisar 346 (54%). Verificou-se que 67,7% das afirmações das propagandas conferiam com suas referências e as demais não conferiam ou conferiam parcialmente. Entre as propagandas analisadas, foi observada média de 2,5 (1-28) referências citadas por propaganda. No corpo das propagandas, foram identificadas 639 informações que estavam explicitamente associadas à pelo menos uma das referências citadas (média de 3,5 informações por propaganda). CONCLUSÕES: Os resultados evidenciaram a dificuldade de acesso às referências. As mensagens de eficácia, segurança, custos, entre outras, nem sempre estão respaldadas por estudos científicos. São necessárias mudanças nas exigências legais e fiscalização efetiva das promoções de medicamentos.

          Translated abstract

          OBJECTIVE: According to the World Health Organization, medicinal drug promotion should be reliable, accurate, truthful, informative, balanced, up-to-date and capable of substantiation. The objective of the present study was to review psychoactive drug advertisements to physicians as for information consistency with the related references and accessibility of the cited references. METHODS: Data was collected in the city of Araraquara, Southeastern Brazil, in 2005. There were collected and reviewed 152 drug advertisements, a total of 304 references. References were requested directly from pharmaceutical companies' customer services and searched in UNESP (Ibict, Athenas) and BIREME (SciELO, PubMed, free-access indexed journals) library network and CAPES journals. Advertisement statements were checked against references using content analysis. RESULTS: Of all references cited in the advertisements studied, 66.7% were accessed. Of 639 promotional statements identified, 346 (54%) were analyzed. The analysis showed that 67.7% of promotional statements in the advertisements were consistent with their references, while the remaining was either partially consistent or inconsistent. Of the material analyzed, an average 2.5 (1-28) references was cited per advertisement. In the text body, there were identified 639 pieces of information clearly associated with at least one cited reference (average 3.5 pieces of information per advertisement). CONCLUSIONS: The study results evidenced difficult access to the references. Messages on efficacy, safety and cost, among others, are not always supported by scientific studies. There is a need for regulation changes and effective monitoring of drug promotional materials.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Interactions between physicians and the pharmaceutical industry: what does the literature say?

          J Lexchin (1993)
          To determine the effect of three types of interaction between physicians and the pharmaceutical industry--company-funded clinical trials, company-sponsored continuing medical education (CME) and information for physicians supplied by pharmaceutical detailers--on orientation and quality of clinical trials, content of CME courses and physicians' prescribing behaviour. MEDLINE and HEALTH searches for English-language articles published from 1978 to 1993, supplemented by material from the author's personal collection. A total of 227 papers from the MEDLINE and HEALTH searches and about 2000 items from the author's library were initially reviewed. The following selection criteria were used: studies conducted in Australia, Canada, New Zealand, Britain and the United States; studies conducted after 1977; quantitative surveys containing details of the survey methods; studies on the orientation and quality of company-funded clinical trials and on the content of CME courses giving explicit criteria used in the evaluation; and reports on the outcome of interactions stating how the outcomes were assessed. Thirty-six studies met these criteria. Information was extracted on five topics: physicians' attitudes toward drug industry interactions, frequency with which physicians participate in the interactions, orientation and quality of company-funded clinical trials, content of company-sponsored CME courses and changes in physicians' prescribing behaviour as a result of an interaction. Although most physicians participate only occasionally in company-sponsored clinical trials, most see detailers and attend company-sponsored CME courses. However, physicians do not have a very high opinion of the information from detailers or of company-sponsored CME events. Many doctors regard pharmaceutical companies as an important source of funding for clinical trials, but they also have concerns about accepting money from this source. Company funding of clinical trials may affect the quality of the trials and the types of research that physicians undertake. Company-sponsored CME courses may have a commercial bias even if conducted under guidelines designed to ensure the independence of the event. All three types of interactions affect physicians' prescribing behaviour and, in the case of obtaining information from detailers, physicians' prescribing practices are less appropriate as a result of the interaction. Physicians are affected by their interactions with the pharmaceutical industry. Further research needs to be done in most cases to determine whether such interactions lead to more or less appropriate prescribing practices. The CMA's guidelines on this topic should be evaluated to see whether they are effective in controlling physician-industry interactions. Further measures may be necessary if the guidelines fail to prevent negative effects on prescribing practices.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Accuracy of pharmaceutical advertisements in medical journals.

              Because of the effect of the ever-growing evidence-based medicine movement on prescribing behaviour of doctors, the pharmaceutical industry incorporates bibliographical references to clinical trials that endorse their products in their advertisements. We aimed to assess whether the references about efficacy, safety, convenience, or cost of antihypertensive and lipid-lowering drugs included in advertisements supported the promotional claims. We assessed all advertisements for antihypertensive and lipid-lowering drugs published in six Spanish medical journals in 1997 that had at least one bibliographical reference. Two pairs of investigators independently reviewed the advertisements to see whether the studies quoted to endorse the advertising messages supported the corresponding claims. We identified 264 different advertisements for antihypertensive drugs and 23 different advertisements for lipid-lowering drugs. We recorded at least one reference in 31 advertisements in the antihypertensive group and at least one reference in every seven advertisements in the lipid-lowering group, providing a total of 125 promotional claims with references. We could not retrieve 23 (18%) references from monographic works and non-published data on file. 79 (63%) of the 125 references were from journals with a high impact factor; 84 (82%) of the 102 references retrieved were from randomised clinical trials. In 45 claims (44.1%; 95% CI 34.3-54.3) the promotional statement was not supported by the reference, most frequently because the slogan recommended the drug in a patient group other than that assessed in the study. Doctors should be cautious in assessment of advertisements that claim a drug has greater efficacy, safety, or convenience, even though these claims are accompanied by bibliographical references to randomised clinical trials published in reputable medical journals and seem to be evidence-based.
                Bookmark

                Author and article information

                Journal
                rsp
                Revista de Saúde Pública
                Rev. Saúde Pública
                Faculdade de Saúde Pública da Universidade de São Paulo (São Paulo, SP, Brazil )
                0034-8910
                1518-8787
                June 2008
                : 42
                : 3
                : 529-535
                Affiliations
                [02] São Paulo São Paulo orgnameUniversidade Federal de São Paulo orgdiv1Escola Paulista de Medicina orgdiv2Departamento de Psicobiologia Brazil
                [01] Araraquara São Paulo orgnameUniversidade Estadual Paulista orgdiv1Faculdade de Ciências Farmacêuticas. orgdiv2Departamento de Fármacos e Medicamentos Brazil
                Article
                S0034-89102008000300020 S0034-8910(08)04200320
                10.1590/S0034-89102008005000023
                63eade5f-840c-4b58-b75a-48bba01007a7

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 23 July 2007
                : 15 November 2007
                : 08 January 2008
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 25, Pages: 7
                Product

                SciELO Public Health

                Self URI: Texto completo somente em PDF (PT)
                Self URI: Full text available only in PDF format (EN)
                Categories
                Artigos Originais

                Psicotrópicos,Propagandista de Laboratório,Controle da Publicidade de Produtos,Sistemas de Medicação no Hospital,Política Nacional de Medicamentos,Revisão,Psychotropic Drugs,Drug Promoter,Products Publicity Control,Medication Systems, Hospital,National Drug Policy,Review

                Comments

                Comment on this article